Marine Antimicrobial Agents

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (31 August 2018) | Viewed by 27902

Special Issue Editor


E-Mail Website
Guest Editor
American Institutes for Research, 1000 Thomas Jefferson St NW, Washington, DC 20007, USA
Interests: antibacterial agents; cation-pi and sigma hole-based protein–ligand complex investigations; the interface of chemistry and art; improving low-income accessibility of hands-on chemical instrumentation-based experiments in analytical chemistry and biochemistry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue contains communications, full research papers, and reviews pertaining to the following topics:

(1) Purification, spectroscopic structure elucidation, and biological characterization (with requisite in vitro antibacterial MIC (uM) and mammalian cytotoxicity study (uM)) of novel antibacterial compounds derived from marine organisms.

Marine antibacterial compounds include:

- bacteriostatic or bacteriocidal agents

- quorum sensing antagonists

- antiproliferative agents, e.g., inhibitors of bacterial enzymes disrupting the tissue matrix

- inhibitors of cancer-causing or cancer-aiding effects of bacterial infection

Full spectroscopic data (original proton, carbon-13, 2D NMR spectra, and HRMS) and purity confirmation (LCMS chromatogram or elemental analysis) must be included.

(2) Study of biological marine antibacterial agents

- bacteriophages 

- predatory bacteria

(must include in vitro animal cell cytotoxicity study against cells from relevant species, e.g., poultry cell cytotoxicity for an antibacterial agent eliminating a poultry infection)

(3) Investigation of antibacterial selectivity of known or new marine antibacterial agents towards marine vs. terrestrial bacteria

(4) Mechanism of action of marine antibacterial agents, new or previously reported

Dr. Miguel O. Mitchell
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Antibacterial agent
  • Quorum-sensing antagonist
  • Predatory bacteria
  • Bacteriophage
  • Antiproliferative
  • Anticancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (5 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 1755 KiB  
Article
20-Nor-Isopimarane Epimers Produced by Aspergillus wentii SD-310, a Fungal Strain Obtained from Deep Sea Sediment
by Xiao-Dong Li, Xin Li, Xiao-Ming Li, Gang-Ming Xu, Yang Liu and Bin-Gui Wang
Mar. Drugs 2018, 16(11), 440; https://doi.org/10.3390/md16110440 - 9 Nov 2018
Cited by 24 | Viewed by 3878
Abstract
Four new uncommon 20-nor-isopimarane diterpenoid epimers, aspewentins I−L (14), together with a new methylated derivative of 3, aspewentin M (5), were isolated from the deep sea sediment-derived fungus Aspergillus wentii SD-310. The very similar structures of [...] Read more.
Four new uncommon 20-nor-isopimarane diterpenoid epimers, aspewentins I−L (14), together with a new methylated derivative of 3, aspewentin M (5), were isolated from the deep sea sediment-derived fungus Aspergillus wentii SD-310. The very similar structures of these epimers made the separation and purification procedures difficult. The structures of compounds 15 were illustrated based on spectroscopic analysis, and the absolute configurations of compounds 15 were unambiguously determined by the combination of NOESY, time-dependent density functional (TDDFT)-ECD calculations, and X-ray crystallographic analysis. These metabolites represented the rare examples of 20-nor-isopimarane analogues possessing a cyclohexa-2,5-dien-1-one moiety. These compounds were tested for antimicrobial activities against human and aquatic pathogenic bacteria, as well as plant-pathogenic fungi. While compounds 1 and 2 exhibited inhibitory activities against zoonotic pathogenic bacteria such as Escherichia coli, Edwardsiella tarda, Vibrio harveyi, and V. parahaemolyticus, compound 5 showed potent activity against the plant pathogen Fusarium graminearum. Full article
(This article belongs to the Special Issue Marine Antimicrobial Agents)
Show Figures

Figure 1

11 pages, 865 KiB  
Article
Linear Aminolipids with Moderate Antimicrobial Activity from the Antarctic Gram-Negative Bacterium Aequorivita sp.
by Giuseppina Chianese, Fortunato Palma Esposito, Delphine Parrot, Colin Ingham, Donatella De Pascale and Deniz Tasdemir
Mar. Drugs 2018, 16(6), 187; https://doi.org/10.3390/md16060187 - 28 May 2018
Cited by 17 | Viewed by 4735
Abstract
The combination of LC-MS/MS based metabolomics approach and anti-MRSA activity-guided fractionation scheme was applied on the Gram-negative bacterium Aequorivita sp. isolated from shallow Antarctic sea sediment using a miniaturized culture chip technique. This methodology afforded the isolation of three new (1 [...] Read more.
The combination of LC-MS/MS based metabolomics approach and anti-MRSA activity-guided fractionation scheme was applied on the Gram-negative bacterium Aequorivita sp. isolated from shallow Antarctic sea sediment using a miniaturized culture chip technique. This methodology afforded the isolation of three new (13) and four known (47) N-terminal glycine- or serine-bearing iso-fatty acid amides esterified with another iso-fatty acid through their C-3 hydroxy groups. The chemical structures of the new compounds were elucidated using a set of spectroscopic (NMR, [α]D and FT-IR) and spectrometric (HRMS, HRMS/MS) methods. The aminolipids possessing an N-terminal glycine unit (1, 2, 4, 5) showed moderate in vitro antimicrobial activity against MRSA (IC50 values 22–145 μg/mL). This is the first in-depth chemistry and biological activity study performed on the microbial genus Aequorivita. Full article
(This article belongs to the Special Issue Marine Antimicrobial Agents)
Show Figures

Graphical abstract

2312 KiB  
Article
Antimicrobial Peptide Epinecidin-1 Modulates MyD88 Protein Levels via the Proteasome Degradation Pathway
by Bor-Chyuan Su and Jyh-Yih Chen
Mar. Drugs 2017, 15(11), 362; https://doi.org/10.3390/md15110362 - 16 Nov 2017
Cited by 15 | Viewed by 6187
Abstract
The cationic antimicrobial peptide epinecidin-1 was identified from Epinephelus coioides and possesses multiple biological functions, including antibacterial, antifungal, anti-tumor, and immunomodulatory effects. In addition, epinecidin-1 suppresses lipopolysaccharide (LPS)-induced inflammation by neutralizing LPS and ameliorating LPS/Toll-like receptor (TLR)-4 internalization. However, it is unclear whether [...] Read more.
The cationic antimicrobial peptide epinecidin-1 was identified from Epinephelus coioides and possesses multiple biological functions, including antibacterial, antifungal, anti-tumor, and immunomodulatory effects. In addition, epinecidin-1 suppresses lipopolysaccharide (LPS)-induced inflammation by neutralizing LPS and ameliorating LPS/Toll-like receptor (TLR)-4 internalization. However, it is unclear whether the actions of epinecidin-1 depend on the regulation of TLR adaptor protein MyD88 or endogenous TLR signaling antagonists, which include A20, interleukin-1 receptor associated kinase (IRAK)-M, and suppressor of cytokine signaling (SOCS)-1. Our results demonstrate that epinecidin-1 alone does not affect A20, IRAK-M, or SOCS-1 protein levels. However, pre-incubation of epinecidin-1 significantly inhibits LPS-induced upregulation of A20, IRAK-M, and SOCS-1. In addition, epinecidin-1 significantly reduces the abundance of MyD88 protein. Both MG132 (a specific proteasome inhibitor) and Heclin (a specific Smurf E3 ligase inhibitor) are able to abolish epinecidin-1-mediated MyD88 degradation. Thus, our data suggest that epinecidin-1 directly inhibits MyD88 via induction of the Smurf E3 ligase proteasome pathway. Full article
(This article belongs to the Special Issue Marine Antimicrobial Agents)
Show Figures

Figure 1

4488 KiB  
Article
Diversity and Antimicrobial Potential of Predatory Bacteria from the Peruvian Coastline
by Luis Linares-Otoya, Virginia Linares-Otoya, Lizbeth Armas-Mantilla, Cyntia Blanco-Olano, Max Crüsemann, Mayar L. Ganoza-Yupanqui, Julio Campos-Florian, Gabriele M. König and Till F. Schäberle
Mar. Drugs 2017, 15(10), 308; https://doi.org/10.3390/md15100308 - 12 Oct 2017
Cited by 14 | Viewed by 5917
Abstract
The microbiome of three different sites at the Peruvian Pacific coast was analyzed, revealing a lower bacterial biodiversity at Isla Foca than at Paracas and Manglares, with 89 bacterial genera identified, as compared to 195 and 173 genera, respectively. Only 47 of the [...] Read more.
The microbiome of three different sites at the Peruvian Pacific coast was analyzed, revealing a lower bacterial biodiversity at Isla Foca than at Paracas and Manglares, with 89 bacterial genera identified, as compared to 195 and 173 genera, respectively. Only 47 of the bacterial genera identified were common to all three sites. In order to obtain promising strains for the putative production of novel antimicrobials, predatory bacteria were isolated from these sampling sites, using two different bait organisms. Even though the proportion of predatory bacteria was only around 0.5% in the here investigated environmental microbiomes, by this approach in total 138 bacterial strains were isolated as axenic culture. 25% of strains showed antibacterial activity, thereby nine revealed activity against clinically relevant methicillin resistant Staphylococcus aureus (MRSA) and three against enterohemorrhagic Escherichia coli (EHEC) strains. Phylogeny and physiological characteristics of the active strains were investigated. First insights into the chemical basis of the antibacterial activity indicated the biosynthetic production of the known compounds ariakemicin, kocurin, naphthyridinomycin, pumilacidins, resistomycin, and surfactin. However, most compounds remained elusive until now. Hence, the obtained results implicate that the microbiome present at the various habitats at the Peruvian coastline is a promising source for heterotrophic bacterial strains showing high potential for the biotechnological production of antibiotics. Full article
(This article belongs to the Special Issue Marine Antimicrobial Agents)
Show Figures

Figure 1

Review

Jump to: Research

18 pages, 760 KiB  
Review
Recent Advances in Antibacterial and Antiendotoxic Peptides or Proteins from Marine Resources
by Zhenlong Wang, Xiumin Wang and Jianhua Wang
Mar. Drugs 2018, 16(2), 57; https://doi.org/10.3390/md16020057 - 10 Feb 2018
Cited by 22 | Viewed by 5841
Abstract
Infectious diseases caused by Gram-negative bacteria and sepsis induced by lipopolysaccharide (LPS) pose a major threat to humans and animals and cause millions of deaths each year. Marine organisms are a valuable resource library of bioactive products with huge medicinal potential. Among them, [...] Read more.
Infectious diseases caused by Gram-negative bacteria and sepsis induced by lipopolysaccharide (LPS) pose a major threat to humans and animals and cause millions of deaths each year. Marine organisms are a valuable resource library of bioactive products with huge medicinal potential. Among them, antibacterial and antiendotoxic peptides or proteins, which are composed of metabolically tolerable residues, are present in many marine species, including marine vertebrates, invertebrates and microorganisms. A lot of studies have reported that these marine peptides and proteins or their derivatives exhibit potent antibacterial activity and antiendotoxic activity in vitro and in vivo. However, their categories, heterologous expression in microorganisms, physicochemical factors affecting peptide or protein interactions with bacterial LPS and LPS-neutralizing mechanism are not well known. In this review, we highlight the characteristics and anti-infective activity of bifunctional peptides or proteins from marine resources as well as the challenges and strategies for further study. Full article
(This article belongs to the Special Issue Marine Antimicrobial Agents)
Show Figures

Figure 1

Back to TopTop